• CN
  • CN
  • RESEARCH

  • R&D BASES
  • UPCOMING PRODUCTS
  • QUALITY MANAGEMENT
  • COMPLIANCE MANAGEMENT
  • RESEARCH
  • PRODUCTS & SERVICES

  • PRODUCTS
  • LOGISTICS & DISTRIBUTION
  • PRODUCT PROMOTION
  • INTERNATIONAL TRADE
  • PRODUCTS & SERVICES
  • Newsroom

  • CONTACT US

  • PRODUCTS & SERVICES

  • PRODUCTS
  • LOGISTICS & DISTRIBUTION
  • PRODUCT PROMOTION
  • INTERNATIONAL TRADE
  • Newsroom

  • CONTACT US

  • Chongqing Zhifei Biological Products Co.,Ltd.

    MILESTONES
    2002
    The predecessor company was integrated into Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), and entered biological products industry.
    2003
    Beijing Luzhu Biopharmaceutical Co., Ltd. was founded and the company started the construction of its R&D and manufacturing facilities.
    2004
    Chongqing Zhiren Biotech Co., Ltd. was founded, which mainly engages in distribution of biological products and generic drugs.
    2006
    The first self-developed product — Meningococcal Group A and C Conjugate Vaccine (MenAC Conj Vaccine) received market approval.
    2007
    Self-developed product — Group ACYW135 Meningococcal Polysaccharide Vaccine (MenACYW135 Ps Vaccine) received market approval.
    2008
    MenAC Conj Vaccine and MenACYW135 Ps Vaccine launched onto the domestic market.
    2009
    Zhifei was restructured into a joint-stock company.
    2010
    Zhifei successfully went listed on Chinext, Shenzhen Stock Exchange.
    2012
    In 2012, Zhifei launched an independently developed new product - Hib vaccine.
    2014
    In 2014, MenAC-Hib, independently-developed by Zhifei, first product of its kind worldwide was launched filling the blank of combination vaccine of meningococcus and Haemophilus influenzae.
    In the same year, Zhifei founded Chongqing Zhirui Investment Co., Ltd., an equity investment company, with self-funding and the contribution of Mr. Jiang Rensheng, the controlling shareholder and actual controller of Zhifei, to make presence in a broader biological industry.
    2015
    In 2015, Zhifei signed a strategic cooperation agreement with Institut Pasteur of Shanghai of Chinese Academy of Sciences.
    2016
    In 2016, Zhifei founded Zhifei Airport (Beijing) International Trade Co., Ltd.
    2017
    In 2017, Zhifei renewed its distribution and promotion cooperation agreement with Merck Sharp & Dohme of USA (MSD) to import 4-valent Human Papilloma Virus Vaccine (Saccaromyces Cerevisiae) to provide health protection for Chinese women aged 20-45 years.
    2018
    In 2018, Zhifei signed a supplementary agreement with MSD to import 9-valent Human Papilloma Virus Vaccine (Saccaromyces Cerevisiae) to provide health protection for Chinese women aged 16-26 years.
    Zhifei donated RMB10 million to support the establishment of the first Escort Disease Control Fund in China.